Cancer Research Campaign Technology Limited

Renovo Limited

Jane Kelly

Geoffrey Paul Margison

Amanda Jean Watson

Joseph Anthony Rafferty

Dorothy Josephine Donnelly

Rhoderick Hugh Elder

Mark Andrew Willington

Thomas Brian McMurry

Joan Elizabeth McCormick

Paul Murray

Christophe Carola

Robert Stanley McElhinney

Sharon O'Kane

Nick Occleston

Hugh Gerard Laverty

Mark Ferguson

Robert Stanley McBlhinney

Wayne Burrill

Mark Ross Middleton

The invention provides pharmaceutical compositions comprising TGF-&#x3b2; superfamily members and sugars, the compositions allowing improved recovery and/or increased biological activity of the TGF-&#x3b2; superfamily member incorporated therein. The invention also relates to uses of sugars to improve the recovery or increase the biological activity of TGF-&#x3b2; superfamily members in a pharmaceutical composition. Uses of the pharmaceutical compositions are also described, particularly with reference to wound healing and fibrosis. Furthermore, the invention discloses medicaments for the prevention or reduction of injection pain.

Pharmaceutical compositions

The present invention provides certain 6-hetarylalkyloxy pyrimidine derivatives of formula II ##STR1## wherein R is (i) a cyclic group having at least one 5- or 6-membered heterocyclic ring, optionally with a carbocyclic or heterocyclic ring fused thereto, the or each heterocyclic ring having at least one hetero atom chosen from O, N, or S, or a substituted derivative thereof; or (ii) phenyl or a substituted derivative thereof,

Pyrimidine derivatives and guanine derivatives, and their use in

O.sup.6 -hetarylalkyl- or naphthylalkylguanine derivatives of the formula ##STR1## wherein Y is H, ribosyl, deoxyribosyl, or R'XCHR',

O.sup.6 -substituted guanine derivatives, a process for their

The present invention provides certain 6-hetarylalkyloxy pyrimidine derivatives of formula II ##STR1## wherein R is (i) a cyclic group having at least one 5- or 6-membered heterocyclic ring, optionally with a carbocyclic or heterocyclic ring fused thereto, the or each heterocyclic ring having at least one hetero atom chosen from O, N, or S, or a substituted derivative thereof; or (ii) phenyl or a substituted derivative thereof, R.sup.2 is selected from H, C.sub.1 -C.sub.5 alkyl, halogen or NH.sub.2, R.sup.4 and R.sup.5 which are the same or different are selected from H, NH.sub.2 or NO.sub.n where n=1 or 2, or R.sup.4 and R.sup.5 together with the pyrimidine ring form a 5-or 6-membered ring structure containing one or more heterocyclic atoms, and pharmaceutically acceptable salts thereof, exhibit the ability to deplete O.sup.6 -alkylguanine-DNA alkyltransferase (ATase) activity.

Pyrimidine and purine derivatives and their use in treating tumour cells

Growing community of inventors

Manchester, United Kingdom

Jane Kelly